HK1061564A1 - Polymorph forms of n-(2,3-dimethyl-5,6,7,8-tetrahydrofuro2,3-b quinolin-4- yl)-2-(2-oxopyrrolidin-1-yl)-acetamide - Google Patents

Polymorph forms of n-(2,3-dimethyl-5,6,7,8-tetrahydrofuro2,3-b quinolin-4- yl)-2-(2-oxopyrrolidin-1-yl)-acetamide

Info

Publication number
HK1061564A1
HK1061564A1 HK04104491.2A HK04104491A HK1061564A1 HK 1061564 A1 HK1061564 A1 HK 1061564A1 HK 04104491 A HK04104491 A HK 04104491A HK 1061564 A1 HK1061564 A1 HK 1061564A1
Authority
HK
Hong Kong
Prior art keywords
oxopyrrolidin
quinolin
acetamide
dimethyl
polymorph forms
Prior art date
Application number
HK04104491.2A
Other languages
English (en)
Inventor
Haruko Yamabe
Takayuki Ishige
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of HK1061564A1 publication Critical patent/HK1061564A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK04104491.2A 2001-04-19 2004-06-21 Polymorph forms of n-(2,3-dimethyl-5,6,7,8-tetrahydrofuro2,3-b quinolin-4- yl)-2-(2-oxopyrrolidin-1-yl)-acetamide HK1061564A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001121681 2001-04-19
JP2001121682 2001-04-19
PCT/JP2002/003916 WO2002085910A1 (en) 2001-04-19 2002-04-19 Polymorph forms of n-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2- oxopyrrolidin -1 -yl)acetamide

Publications (1)

Publication Number Publication Date
HK1061564A1 true HK1061564A1 (en) 2004-09-24

Family

ID=26613875

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04104491.2A HK1061564A1 (en) 2001-04-19 2004-06-21 Polymorph forms of n-(2,3-dimethyl-5,6,7,8-tetrahydrofuro2,3-b quinolin-4- yl)-2-(2-oxopyrrolidin-1-yl)-acetamide

Country Status (11)

Country Link
US (1) US6884805B2 (zh)
EP (1) EP1392696B1 (zh)
JP (1) JP2004525985A (zh)
KR (1) KR100909923B1 (zh)
CN (1) CN100484939C (zh)
AT (1) ATE492549T1 (zh)
CA (1) CA2439117C (zh)
DE (1) DE60238674D1 (zh)
HK (1) HK1061564A1 (zh)
TW (1) TWI332503B (zh)
WO (1) WO2002085910A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101063605B1 (ko) * 2003-01-08 2011-09-07 미쓰비시 타나베 파마 코퍼레이션 정신분열증 치료제
US20090088449A1 (en) * 2006-02-07 2009-04-02 Mitsubishi Tanabe Pharma Corporation 4-acylaminopyridine derivative mediated neurogenesis
JP2010502722A (ja) * 2006-09-08 2010-01-28 ブレインセルス,インコーポレイティド 4−アシルアミノピリジン誘導体を含む組み合わせ

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2029497C (en) * 1989-11-08 2002-06-04 Kunihiro Ninomiya (Deceased) 4-acylaminopyridine derivative

Also Published As

Publication number Publication date
TWI332503B (en) 2010-11-01
KR20030097833A (ko) 2003-12-31
KR100909923B1 (ko) 2009-07-29
ATE492549T1 (de) 2011-01-15
CN1498219A (zh) 2004-05-19
JP2004525985A (ja) 2004-08-26
CA2439117C (en) 2011-02-08
DE60238674D1 (de) 2011-02-03
CA2439117A1 (en) 2002-10-31
CN100484939C (zh) 2009-05-06
WO2002085910A1 (en) 2002-10-31
EP1392696B1 (en) 2010-12-22
US6884805B2 (en) 2005-04-26
EP1392696A1 (en) 2004-03-03
US20040122034A1 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
GEP20105053B (en) Bicyclic [3.1.0] heteroaryl amides as type i glycine transport inhibitors
AP2002002637A0 (en) Novel piperazine
CA2150123A1 (en) Aminomethylene substituted non-aromatic heterocycles
PT1671949E (pt) Piridinilaminas substituídas
NO20053644L (no) (2S)-2-[(4S)-4-(2,2-difluorvinyl)-2-oksopyrrolidinyl ]butanamid og farmasoytisk preparat
MXPA02012712A (es) N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas.
MXPA04000278A (es) Uso de antagonistas del receptor nk-1 con estructura piridinica para tratamiento de lesiones cerebrales, espinales o neuronales.
IL151172A0 (en) Amine derivatives, their preparation and use as bax modulators
ATE347553T1 (de) Amino-substituierte pyrazolo 1,5-aö-1,5- pyrimidine und pyrazolo 1,5-aö-1,3,5-triazine
AP2003002841A0 (en) Quinazolines as MMP-13 inhibitors
HK1044282A1 (zh) 作為趨化因子受體活性調節劑的n-脲基烷基-哌啶化合物
NO970162L (no) Substituerte pyrimidinforbindelser og anvendelse derav
YU57603A (sh) Inhibitori fosfodiesteraze 4
WO2001098268A3 (en) Piperidine amides as modulators of chemokine receptor activity
HU0100973D0 (en) Use of heteroaryl substituted n-(indole-2-carbonyl)-amide derivatives for the treatment of infections
WO2001028987A8 (en) Benzylcycloalkyl amines as modulators of chemokine receptor activity
CA2135783A1 (en) Substituted (arylalkoxybenzyl) amino-propanamide derivatives and process for their preparation
FI970469A0 (fi) Bentsimidatsolijohdannaisia, joilla on dopaminerginen aktiivisuus
MXPA05004273A (es) Derivados de fenilalquil y piridilalquil piperazina.
HK1061564A1 (en) Polymorph forms of n-(2,3-dimethyl-5,6,7,8-tetrahydrofuro2,3-b quinolin-4- yl)-2-(2-oxopyrrolidin-1-yl)-acetamide
AP2002002595A0 (en) Heterocyclic amide derivatives.
DK1049672T3 (da) Azetidincarboxamid-derivater til behandling af CNS-lidelser
BG105247A (en) N-substituted azabicycloheptane derivatives, production and use thereof
MY136138A (en) Hexacyclic compounds
DK1049670T3 (da) Azetidincarboxamidderivater til behandling af CNS-lidelser

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150419